US Trade Bodies Fight NIH Plan to Subsume Office of Dietary Supplements
Four major US trade associations have formally opposed an NIH reorganisation that folds the Office of Dietary Supplements into the Office of Nutrition Research. The move threatens statutory research mandates and independent analytical standard development.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington, United States — 26 October 2026. Four leading trade organisations have formally challenged the National Institutes of Health (NIH) over proposed structural changes that threaten the autonomy of the Office of Dietary Supplements (ODS). In joint comments submitted on 23 October, the American Herbal Products Association (AHPA), Consumer Healthcare Products Association (CHPA), Council for Responsible Nutrition (CRN), and United Natural Products Alliance (UNPA) contested plans to shift ODS from a standalone entity within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) into the subordinate Office of Nutrition Research (ONR).
The coalition warns that subordinating ODS within ONR undermines its statutory mandate established under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Submerging ODS into broad macronutrient and general public health nutrition research creates administrative barriers and dilutes dedicated federal capital allocated to dietary supplement science. Standalone ODS operations have historically driven analytical method development, reference material validation, and the maintenance of essential industry tools, including the Dietary Supplement Label Database.
For supplement manufacturers, analytical consistency is tied directly to 21 CFR Part 111 compliance. Independent ODS programmes validate chromatographic and spectroscopic testing protocols used by quality control laboratories to verify botanical identity and combat raw material adulteration. If ODS loses direct governance over its research priorities, brand owners face higher compliance expenditure, as private testing consortia and finished product manufacturers will be forced to fund bespoke assay validations for active marker compounds.
What this means for United States
Brand owners and contract manufacturers operating in the US face increased exposure if federal supplement science loses institutional independence. ODS research directly informs FDA safety reviews, FTC claim substantiation, and analytical reference standards across the $60bn domestic market. Submerging ODS within ONR risks siphoning federal research grants into broad public nutrition policy, slowing safety evaluations for emerging functional ingredients. To mitigate testing volatility, procurement teams should audit their raw material testing specifications, ensuring external laboratories do not rely solely on federally supported validation pipelines. Brands expanding claim portfolios must maintain independent clinical dossiers rather than relying on anticipated federal ODS research initiatives.
Many leading brands in this category are manufactured in partnership with Supplement Factory.